Atara Biotherapeutics Inc.

13.34-0.6000-4.30%Vol 91.08K1Y Perf 63.87%
Apr 16th, 2021 10:13 DELAYED
BID13.29 ASK13.34
Open13.93 Previous Close13.94
Pre-Market- After-Market-
 - -%  - -
Target Price
37.00 
Analyst Rating
Moderate Buy 1.67
Potential %
178.20 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.12B 
Earnings Rating
Sell
Price Range Ratio 52W %
28.39 
Earnings Date
5th May 2021

Today's Price Range

13.2413.93

52W Range

7.4528.20

5 Year PE Ratio Range

-5.50-4.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.23%
1 Month
-15.52%
3 Months
-25.09%
6 Months
-0.50%
1 Year
63.87%
3 Years
-64.53%
5 Years
-34.37%
10 Years
-

TickerPriceChg.Chg.%
ATRA13.34-0.6000-4.30
AAPL134.33-0.1700-0.13
GOOG2 295.21-1.4500-0.06
MSFT259.970.47000.18
XOM56.62-0.3600-0.63
WFC42.970.73001.73
JNJ160.860.47000.29
FB306.71-1.1100-0.36
GE13.46-0.0900-0.66
JPM153.771.60001.05
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.73-0.95-30.14
Q03 2020-1.10-0.9216.36
Q02 2020-1.21-1.145.79
Q01 2020-1.36-1.2011.76
Q04 2019-1.30-1.36-4.62
Q03 2019-1.40-1.316.43
Q02 2019-1.45-1.60-10.34
Q01 2019-1.48-1.442.70
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.93-2.20Negative
6/2021 QR-0.96-4.35Negative
12/2021 FY-3.81-3.25Negative
12/2022 FY-3.78-10.85Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.93
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume91.08K
Shares Outstanding83.62M
Trades Count950
Dollar Volume17.64M
Avg. Volume856.19K
Avg. Weekly Volume532.38K
Avg. Monthly Volume825.00K
Avg. Quarterly Volume852.50K

Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock closed at 13.94 per share at the end of the most recent trading day (a 0.65% change compared to the prior day closing price) with a volume of 1.07M shares and market capitalization of 1.12B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Atara Biotherapeutics Inc. CEO is Pascal Touchon.

The one-year performance of Atara Biotherapeutics Inc. stock is 63.87%, while year-to-date (YTD) performance is -28.99%. ATRA stock has a five-year performance of -34.37%. Its 52-week range is between 7.45 and 28.2, which gives ATRA stock a 52-week price range ratio of 28.39%

Atara Biotherapeutics Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 2.57, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.78%, a ROC of -87.48% and a ROE of -78.73%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Atara Biotherapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Atara Biotherapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Atara Biotherapeutics Inc. is Moderate Buy (1.67), with a target price of $37, which is +178.20% compared to the current price. The earnings rating for Atara Biotherapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atara Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atara Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.07, ATR14 : 1.02, CCI20 : -84.20, Chaikin Money Flow : -0.12, MACD : -1.24, Money Flow Index : 39.01, ROC : -0.43, RSI : 41.50, STOCH (14,3) : 33.85, STOCH RSI : 1.00, UO : 46.01, Williams %R : -66.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atara Biotherapeutics Inc. in the last 12-months were: Joseph Newell (Option Excercise at a value of $170 100), Joseph Newell (Sold 37 083 shares of value $669 172 ), Pascal Touchon (Sold 29 740 shares of value $425 811 ), Utpal Koppikar (Sold 11 537 shares of value $163 426 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
5 (71.43 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (33.33 %)
2 (28.57 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.57
Moderate Buy
1.86

Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

CEO: Pascal Touchon

Telephone: +1 650 278-8930

Address: 611 Gateway Boulevard, South San Francisco 94080, CA, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

News

Stocktwits